drugset / Trial / NCT01290471
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open label study to assess the safety and tolerability of U3 1565, determine maximum tolerated dose (MTD) or establish maximum administered dose (MAD) safety and tolerability.
Timeline
- Start
- 2011-01
- Primary completion
- 2013-01
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | U3 1565 | Unknown | 2 mg/kg | Intravenous |
| Subject | U3 1565 | Unknown | 8 mg/kg | Intravenous |
| Subject | U3 1565 | Unknown | 16 mg/kg | Intravenous |
| Subject | U3 1565 | Unknown | 24 mg/kg | Intravenous |